Roche Holding AG (RHHBY)
OTCMKTS · Delayed Price · Currency is USD
49.00
-0.07 (-0.14%)
At close: Jun 3, 2026
Roche Holding AG Revenue
In the year 2025, Roche Holding AG had annual revenue of 63.36B CHF with 1.54% growth. Roche Holding AG had revenue of 31.51B in the half year ending December 31, 2025, with 5.64% growth.
Revenue
63.36B CHF
Revenue Growth
+1.54%
P/S Ratio
3.94
Revenue / Employee
613.62K CHF
Employees
103,249
Market Cap
314.53B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 63.36B | 961.00M | 1.54% |
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 594.41M |
| Vaxart | 255.61M |
| Glass House Brands | 181.98M |
| Elite Pharmaceuticals | 140.12M |
| Northwest Biotherapeutics | 1.50M |
| Silence Therapeutics | 839.00K |
| Tian'an Technology Group | 734.89K |
Roche Holding AG News
- 21 hours ago - Ideaya Biosciences announces IDE892 collaboration with Roche - TheFly
- 1 day ago - Roche Holding AG Transcript: Investor update - Transcripts
- 1 day ago - Roche Holding AG Slides: Investor update - Filings
- 1 day ago - Genentech announces FDA acceptance of giredestrant NDA under Priority Review - TheFly
- 2 days ago - FDA Accepts New Drug Application for Genentech's Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting - Business Wire
- 2 days ago - FDA accepts New Drug Application for Roche's giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting - GlobeNewsWire
- 3 days ago - Roche to present new data advancing its obesity portfolio at the American Diabetes Association's 2026 Scientific Sessions - GlobeNewsWire
- 3 days ago - Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association's 2026 Scientific Sessions - Business Wire